AIV Logo AIV Assistant

Loading...

 Logo PolyPid Ltd. - PYPD 3.50 USD

EPS
-4.24
P/B
460.00
ROE
-853.05
Beta
1.25
Target Price
12.75 USD

3.500 USD

3.500 USD

Daily: +0.00%
Key Metrics

EPS: -4.24

Book Value: 0.01

Price to Book: 460.00

Debt/Equity: 10265.12

% Insiders: 25.652%

Estimates

Forward P/E: -1.36

Forward EPS: -2.70

Target Mean Price: 12.75

 Logo About PolyPid Ltd. - (PYPD)

Country: Israel

Sector: Health Care

Website: http://www.polypid.com

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Exchange Ticker
NGM (Sweden) PYPD

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 21, 2023 0.03
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion